This study, called SATURN, is looking at whether people who have had a spontaneous lobar intracerebral hemorrhage (ICH), which is a type of bleeding in the brain, should continue taking statin drugs or stop taking them. You may be able to join if you are 50 or older, had this type of ICH, and were already taking a statin drug. The study wants to see if continuing or stopping statins affects your risk of having another ICH within 24 months. The study is currently unclear on its recruitment status but plans to enroll 1456 participants.

Study design

This is a multi-center, randomized study where participants will be assigned by chance to either continue or stop taking their statin medication. It is an open-label study, meaning both you and your doctors will know which treatment you are receiving.

What's involved

You would undergo baseline testing for your APOE genotype and be followed for 24 months. If you join the optional MRI study, you would have an MRI within 7 days of randomization and another at the end of the follow-up period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 24 months to check for recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.